No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study

Transplantation

Volumn 87, Issue 4, 2009, Pages 546-548

  Delgado, Julio C ^a,b,c   Fuller, Anne ^c   Ozawa, Miyuki ^d   Smith, Lonnie ^c   Terasaki, Paul I ^d   Shihab, Fuad S ^c   Eckels, David D ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Corticosteroids; Donor specific antibody; HLA antibody

Indexed keywords

CORTICOSTEROID; HLA ANTIBODY; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY GRAFT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CADAVER; DONOR; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FOLLOW UP; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVING DONOR; MIDDLE AGED; PROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; ADULT; CADAVER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE DONORS;

EID: 65649113570     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181949d2e     Document Type: Article

References (15)

1. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829.
2. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: Changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006; 1: 1080.
3. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
4. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137: 364.
5. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306.
6. Kandaswamy R, Melancon J, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - An interim analysis. Am J Transplant 2005; 5: 1529.
7. Alexander JW, Goodman HR, Cardi M, et al. Simultaneous corticoste-roid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006; 19: 295.
8. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
9. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
10. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
11. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
12. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
13. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408.
14. Cupps TR, Edgar LC, Thomas CA, et al. Multiple mechanisms of B cell immunoregulation in man after administration of in vivo corticoste-roids. J Immunol 1984; 132: 170.
15. Mueller T. Mechanisms of action of thymoglobulin. Transplantation 2007; 84(suppl): S5.